{"id":428,"date":"2025-12-10T01:35:25","date_gmt":"2025-12-10T01:35:25","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=428"},"modified":"2025-12-10T01:35:27","modified_gmt":"2025-12-10T01:35:27","slug":"china-bd-2025-fosun-pharmas-subsidiary-yao-pharma-and-pfizer-enter-into-a-2-billion-usd-license-on-glp-1r-agonists-yp05002","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/428.html","title":{"rendered":"[China BD 2025] Fosun Pharma&#8217;s Subsidiary Yao Pharma and Pfizer Enter into a 2 Billion USD License on GLP-1R Agonists YP05002"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Announced Date: 2025-12-09 (December 9, 2025)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor (Seller): Chongqing Yao Pharmaceutical, Subsidiary of Fosun Pharma (China)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee (Buyer): Pfizer<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Name: YP05002<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Modality: Small Molecule<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Target: glucagon-like peptide-1 receptor (GLP-1R) agonists<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Potential Indication: chronic weight management, type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), among others. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Currently Stage: Phase 1 clinical development in Australia<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Authority:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Yao Pharma grants Pfizer an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license covers all indications for therapeutic, diagnostic, and prophylactic human and veterinary use. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Under the terms of the agreement, Yao Pharma will complete an ongoing YP05002 Phase 1 clinical trial in Australia and grants Pfizer an exclusive license to further develop, manufacture and commercialize YP05002 worldwide. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Payment Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Yao Pharma will receive <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Upfront payment of $150 million,<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"> Eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $1.935 billion,<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tiered royalties on sales, if approved.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-enters-exclusive-collaboration-and-license-agreement\">Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma | Pfizer<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.fosunpharma.com\/en\/content\/details37_17020.html\">Fosun Pharma&#8217;s Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement _Press Release_News_Fosun Pharma<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Note:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chinese Name<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chongqing Yao Pharmaceutical \u91cd\u5e86\u836f\u53cb\u5236\u836f<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Fosun Pharma \u590d\u661f\u533b\u836f<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-12-09 (December 9, 2025) Licensor (Seller): Chongqing Yao Pharmaceutical, Subsidiary of Fosun Pharma (China) &hellip; <a title=\"[China BD 2025] Fosun Pharma&#8217;s Subsidiary Yao Pharma and Pfizer Enter into a 2 Billion USD License on GLP-1R Agonists YP05002\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/428.html\"><span class=\"screen-reader-text\">[China BD 2025] Fosun Pharma&#8217;s Subsidiary Yao Pharma and Pfizer Enter into a 2 Billion USD License on GLP-1R Agonists YP05002<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-428","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=428"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/428\/revisions"}],"predecessor-version":[{"id":429,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/428\/revisions\/429"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}